





Helicobacter pylori infection status had no influence on upper 
gastrointestinal symptoms: a cross‑sectional analysis of 3,005 
Japanese subjects without upper gastrointestinal lesions 
undergoing medical health checkups
Tomomi Yoshioka1,2 · Eri Takeshita1,2,4 · Yasuhisa Sakata1,2 · Megumi Hara3 · Kayo Akutagawa1,2 · Natsuko Sakata4 · 
Hiroyoshi Endo5 · Takashi Ohyama6 · Keiji Matsunaga4 · Yuichiro Tanaka1,2 · Shinpei Shirai1,2,5 · Yoichiro Ito1,2 · 
Nanae Tsuruoka1,2 · Ryuichi Iwakiri1,2 · Motoyasu Kusano7 · Kazuma Fujimoto1,2,6 
Received: 26 October 2016 / Accepted: 1 March 2017 
© The Author(s) 2017. This article is published with open access at Springerlink.com
Results Helicobacter pylori infection was positive in 894 
subjects out of 3,005 (29.8%). Eradication of Helicobac-
ter pylori was successfully achieved in 440 subjects of 458 
treated. Helicobacter pylori infection had no influence on 
the acid-related dyspepsia evaluated by the questionnaire, 
whereas the mean reflux score was relatively high in the 
Helicobacter pylori native negative subjects compared to 
Helicobacter pylori native positive. Eradication of Heli-
cobacter pylori and time span after the eradication had no 
effect on the upper gastrointestinal symptoms evaluated by 
the questionnaire.
Conclusion Helicobacter pylori infection and history of 
eradication did not affect acid-related dyspepsia symptoms 
in Japanese healthy subjects.
Keywords Reflux esophagitis · Gastroesophageal 
reflux disease (GERD) · Reflux symptoms · Functional 
dyspepsia · Frequency scale for the symptoms of GERD 
(FSSG)
Introduction
An annual survey on public health conducted by the Min-
istry of Health, Labour and Welfare of Japan in 2013 indi-
cated that 27.68% of males and 31.24% of females had 
some clinical symptoms regarding the gastrointestinal tract 
[1]. Several studies in Western countries indicated a rela-
tionship between Helicobacter pylori infection and clinical 
symptoms of the upper gastrointestinal tract, while the ben-
eficial effect of H. pylori eradication on these symptoms 
was complex [2–4]. Improvement of upper gastrointestinal 
tract symptoms after H. pylori eradication is still unclear 
in Japan [5–12], although several prospective randomized 
studies in Asia and South America showed the efficacy of 
Abstract 
Background This study aimed to evaluate the influence 
of Helicobacter pylori infection and its eradication on the 
upper gastrointestinal symptoms of relatively healthy Japa-
nese subjects.
Methods A total of 3,005 subjects (male/female: 
1,549/1,456) undergoing medical health checkups were 
enrolled in the present study, at five hospitals in Saga, 
Japan, from January to December 2013. They had no sig-
nificant findings following upper gastrointestinal endos-
copy. All subjects completed a questionnaire that addressed 
a frequency scale for symptoms of gastroesophageal 
reflux disease. The questionnaire comprised seven ques-
tions regarding reflux symptoms and seven regarding acid-
related dyspepsia, which were answered with a score based 
on the frequency of symptoms. Helicobacter pylori infec-
tion was identified by a rapid urease test and/or H. pylori 
antibody titer, and an eradication history was confirmed by 
the subjects’ medical records.
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eradication therapy [13, 14]. These reports indicate that a 
relationship between dyspepsia symptoms and H. pylori 
infection is still controversial.
Although previous studies indicated that reflux esophagi-
tis was developed following eradication therapy [4, 15], 
recent studies in Japan have indicated that the frequency or 
severity of this esophagitis, evaluated by endoscopy, was 
not serious [16–20]. Evaluation of reflux symptoms after 
eradication can be difficult, and one study in Japan sug-
gested that the reflux symptoms might be improved and/or 
not exacerbated after eradication [21].
The aims of the present cross-sectional study were to 
determine: (1) whether reflux symptoms and acid-related 
dyspepsia were different between H. pylori positive and 
negative subjects; and (2) whether these symptoms were 
influenced by eradication of H. pylori. Using the modified 
frequency scale for symptoms of gastroesophageal reflux 
disease (FSSG) questionnaire [22, 23], upper gastrointesti-
nal symptoms were evaluated in relatively healthy subjects 
presenting for medical health checkups, with no lesion 
revealed by upper gastrointestinal endoscopy.
Patients and methods
A total of 3,505 subjects (male/female: 1,922/1,583) 
received upper gastrointestinal endoscopy during medi-
cal health checkups at five hospitals in Saga, Japan, from 
January to December 2013, as described in a previous study 
[24]. Written informed consent was obtained from all sub-
jects. Among the subjects, 500 were excluded from the pre-
sent analysis: 395 subjects with endoscopic reflux esophagi-
tis (graded according to the Los Angeles classification [25]; 
27 with gastric cancer and/or gastric ulcers; 24 with duo-
denal ulcers; and 54 who were prescribed with anti-acid 
medicines (histamine-2 receptor antagonists or proton pump 
inhibitors), and/or prokinetics. Thus, 3,005 subjects were 
enrolled in the present analysis, all with no lesions which 
could lead to upper gastrointestinal symptoms. H. pylori 
infection was identified by a rapid urease test and/or H. 
pylori antibody titer, and an eradication history was con-
firmed by the subject’s medical record and medical history 
form to confirm the time span after eradication. The suc-
cessfully eradicated subjects were divided into two groups: 
the time span was more than 3 years and less than 3 years.
All subjects completed a modified FSSG question-
naire, which is a self-administered, validated question-
naire comprising 14 questions, with seven regarding 
reflux symptoms and seven regarding acid-related dys-
pepsia [22]. Each symptom is assigned a score [never 
experienced = 0; occasionally (30% of the time) = 1; 
sometimes (50%) = 2; often (70%) = 3; and always 
(100%) = 4]. The seven questions about reflux symptoms 
are: Q1, “Do you get heartburn?”; Q2, “Do you some-
times subconsciously rub your chest with your hand?”; 
Q3, “Do you get heartburn after meals?”; Q4, “Do you 
have an unusual (e.g. burning) sensation in your throat?”; 
Q5, “Do some things get stuck when you swallow?”; Q6, 
“Do you feel a bitter liquid (acid) coming up into your 
throat?”; and Q7, “Do you get heartburn if you bend 
over?”. The seven questions about acid-related dyspepsia 
are: Q8, “Does your stomach get bloated?”; Q9, “Does 
your stomach ever feel heavy after meals?”; Q10, “Do 
you feel sick after meals?”; Q11, “Do you feel full while 
eating meals?”; Q12, “Do you burp a lot?”; Q13, “Do 
you feel pain in the upper abdomen after meals?”; Q14, 
“Do you feel pain in the upper abdomen while fasting?”.
All procedures performed in this study were approved 
by the Ethical Committee of Saga University Hospi-
tal (2014–09–15). Statistical evaluation was carried out 
using the χ2 test and Welch’s t test (using SPSS software, 
version 22; SPSS, Tokyo, Japan), and statistical signifi-
cance was established at a p value of <0.05.
Results
Table 1 shows the background characteristics of all 3,005 
subjects enrolled in the present study. Their average age 
was 54.2 years, and the numbers of male and female sub-
jects were almost equal. The comorbidity rate of hiatus 
herniation was 29.6% (894/3,005). The rate of short seg-
ment Barrett’s esophagus was relatively high (23.7%), 
whereas the rate of long segment Barrett’s esophagus was 
very low (0.3%). Gastric ulcer scars and duodenal ulcer 
scars were detected by endoscopy only in 3.0 and 2.6% 
of subjects, respectively. The rate of H. pylori infection 
was 29.8% (894/3,005: native positive) at the time of the 
subjects’ medical health checkups. A total of 458 subjects 
Table 1  Characteristics of Japanese subjects presenting for medical 
checkups (n = 3,005) evaluated by upper gastrointestinal endoscopy
a Mean ± SD
Age (years) 54.2 ± 9.1
Gender (males: females) 1,549: 1,456
Body mass index (kg/m2)a 22.8 ± 5.2
Number with H. pylori infection 894 (29.8%)
Number with successful eradication of H. pylori 440 (14.6%)
Number with hiatus herniation 888 (29.6%)
Number with Barrett’s esophagus
 Short segment 712 (23.7%)
 Long segment 10 (0.3%)
Number with gastric ulcer scars 91 (3.0%)
Number with duodenal ulcer scars 77 (2.6%)
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had a history of H. pylori eradication therapy. The infec-
tion had been successfully eradicated in 440 subjects 
(14.6%: eradicated negative). As shown in Table 2, the 
eradication therapy had failed in 18 subjects (eradicated 
positive), giving an eradication rate of 96.1% (440/458).
Table 3 shows the FSSG scores for reflux symptoms 
and acid-related dyspepsia compared between H. pylori 
positive and negative subjects. The symptoms evaluated 
by the FSSG were compared between two groups: an H. 
pylori native negative group versus an H. pylori native 
positive group. Age and body mass index (BMI) were not 
different between the groups, and other subject-related 
characteristics were not different between the groups. The 
score for acid-related dyspepsia was not different between 
the H. pylori native negative and positive groups, indicat-
ing that H. pylori infection had no influence on dyspepsia 
symptoms in subjects presenting for medical checkups. In 
contrast, the mean score for reflux symptoms evaluated by 
the FSSG was significantly higher in the H. pylori native 
negative group compared with the native positive group 
(p < 0.05). However, greater response with score reduc-
tion 2 or more for each question regarding reflux symptoms 
(Q1–Q7) were not different between H. pylori native nega-
tive and positive groups (data not shown).
Reflux symptoms and acid-related dyspepsia were also 
compared between the two groups: subjects for whom H. 
pylori eradication was successful (eradicated negative) ver-
sus subjects who were infected with H. pylori and never 
received eradication therapy (native negative). As indicated 
in Table 3 (the lower low), age and BMI were not different 
between the two groups. The acid-related dyspepsia score 
for the successful eradication subjects (eradicated nega-
tive) was not better compared with that for the H. pylori 
positive subjects (native positive). Reflux symptoms in the 
successful eradication subjects (eradicated negative) were 
not exacerbated compared with H. pylori positive sub-
jects (native positive), as the reflux symptoms scores were 
almost the same in these two groups.
Table 4 shows the effect of the time span after eradica-
tion therapy for H. pylori. The time span was not detected 
for 52 out of 440 eradicated subjects. As shown, neither the 
score for reflux symptoms nor the score for acid-related 
dyspepsia depended on the time span after eradication, 
whereas we did not follow up the same subjects as the pre-
sent report was a cross-sectional study.
Discussion
The present study indicated that H. pylori infection had no 
influence on acid-related dyspepsia in relatively healthy 
Japanese subjects presenting for medical checkups. H. 
pylori infection is a major cause of peptic ulcers and gastric 
cancer, but this study excluded these diseases using upper 
gastrointestinal endoscopy. The subjects in the present 
study had fewer clinical symptoms compared with patients 
who visit a hospital, which might be one of the reasons 
there were no differences in dyspepsia between H. pylori 
positive and negative subjects as most of H. pylori related 
dyspeptic patients defined by Roma IV criteria [26] was 
excluded from the present study. Moreover, most previous 
Table 2  Helicobacter pylori infection and eradication therapy (num-
bers of subjects)
History of eradication 
therapy
No eradication therapy
H. pylori positive 18 (eradicated positive) 876 (native positive)
H. pylori negative 440 (eradicated nega-
tive)
1,671 (native negative)
Table 3  Comparison of total scores from FSSG questionnaire for reflux symptoms and acid-related dyspepsia, between Helicobacter pylori 
negative and positive subjects
FSSG frequency scale for the symptoms of gastroesophageal reflux disease, BMI body mass index
a Mean ± SD
H. pylori native negative (n = 1,671) H. pylori native positive (n = 876) p value
Acid-related dyspepsiaa 1.69 ± 2.67 1.64 ± 2.37 0.62
Reflux symptomsa 2.10 ± 2.87 1.85 ± 2.59 0.03
Age (year)a 54.3 ± 7.9 54.0 ± 9.3 0.22
BMI (kg/m2)a 22.9 ± 6.2 22.8 ± 3.3 0.61
Eradicated negative (n = 440) H. pylori native positive (n = 876) p value
Acid-related dyspepsiaa 1.63 ± 2.38 1.64 ± 2.37 0.96
Reflux symptomsa 1.78 ± 2.45 1.85 ± 2.59 0.60
Agea 54.4 ± 7.8 54.0 ± 9.3 0.48
BMIa 23.1 ± 3.5 22.8 ± 3.3 0.13
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Japanese studies have similarly suggested that there is no 
relationship between upper gastrointestinal symptoms (dys-
pepsia) and H. pylori infection [5–12].
The total score for reflux symptoms was higher in the 
H. pylori negative group compared with the H. pylori posi-
tive group. Whereas subjects with Los Angles classifica-
tion grade A–D reflux esophagitis were not included in the 
present study, those subjects with grade M or N [12, 27, 
28] were included. This might be a cause of higher scores 
for reflux symptoms. It is also possible that reflux symp-
toms might be more common in relatively healthy H. pylori 
negative subjects compared with similar H. pylori positive 
subjects in Japan.
Eradication of H. pylori had no influence on upper gas-
trointestinal symptoms in the present study. Regarding 
this eradication, the data were evaluated retrospectively, 
and the eradication itself and the time span after eradica-
tion changed neither the reflux nor the dyspepsia scores 
from the modified FSSG questionnaire. Previous studies 
indicated that endoscopic reflux esophagitis was developed 
after eradication [4, 15–20]. This study excluded endo-
scopic reflux esophagitis, and the upper gastrointestinal 
symptoms assessed by the FSSG were not affected by H. 
pylori eradication in subjects without reflux esophagitis. 
Previous reviews suggested that the time span after eradi-
cation might be important for the clinical symptoms [16, 
18, 27]. Namely, reflux symptoms appeared after the eradi-
cation might be diminished in a time dependent manner 
after the eradication. The present study indicated the time 
span after eradication had no effect on the score of FSSG 
whereas this cross-sectional study did not follow up the 
same subjects.
In summary, the present study indicated that H. pylori 
infection did not affect upper gastrointestinal symptoms in 
relative healthy Japanese subjects presenting for medical 
checkups with no significant upper gastrointestinal lesions.
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